The Adjuvant Nutritional Intervention in Cancer (ANICA) Trial

REFERENCES

• Lockwood K, Moesgaard S, and Folkers K: Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 199, 1504–1508, 1994.
   PubMed Web of Science ®Google Scholar
• Lockwood K, Moesgaard S, Hanioka T, and Folkers K: Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15(Suppl), S231–S240, 1994.
   PubMed Web of Science ®Google Scholar
• Lockwood K, Moesgaard S, Yamamoto T, and Folkers K: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 212, 172–177, 1995.
   PubMed Web of Science ®Google Scholar
• Folkers K: Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun 224, 358–361, 1996.
   PubMed Web of Science ®Google Scholar
• Folkers K, Osterborg A, Nylander M, Morita M, and Mellstedt H: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234, 296–299, 1997.
   PubMed Web of Science ®Google Scholar
• Folkers K, Brown R, Judy WV, and Morita M: Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 192, 241–245, 1993.
   PubMed Web of Science ®Google Scholar
• Christophersen OA, and Haug A: Animal products, diseases and drugs: a plea for better integration between agricultural sciences, human nutrition and human pharmacology. Lipids Health Dis 10, 16, 2011.
   PubMed Web of Science ®Google Scholar
• Timoshenko AV, Xu G, Chakrabarti S, Lala PK, and Chakraborty C: Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 289, 265–274, 2003.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Villasana V, Gutiérrez-Puente Y, and Tari AM: Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells. Oncol Rep 30, 1506–1510, 2013.
   PubMed Web of Science ®Google Scholar
• Karavitis J, and Zhang M: COX2 regulation of breast cancer bone metastasis. Oncoimmunology 2, e23129, 2013.
   PubMed Web of Science ®Google Scholar
• Lin F, Luo J, Gao W, Wu J, Shao Z, et al.: COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness. Tumour Biol 34, 2817–2826, 2013.
   PubMed Web of Science ®Google Scholar
• Rozic JG, Chakraborty C, and Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93, 497–506, 2001.
   PubMed Web of Science ®Google Scholar
• Larkins TL, Nowell M, Singh S, and Sanford GL: Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 6, 181, 2006.
   PubMed Web of Science ®Google Scholar
• Karavitis J, Hix LM, Shi YH, Schultz RF, Khazaie K, et al.: Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PLoS One 7, e46342, 2012.
   PubMed Web of Science ®Google Scholar
• Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, and Lala PK: Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest 92, 1115–1128, 2012.
   PubMed Web of Science ®Google Scholar
• Na YR, Yoon YN, Son DI, and Seok SH: Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS One 8, e63451, 2013.
   PubMed Web of Science ®Google Scholar
• Li WB, Höllriegl V, Roth P, and Oeh U: Influence of human biokinetics of strontium on internal ingestion dose of 90Sr and absorbed dose of 89Sr to organs and metastases. Radiat Environ Biophys 47, 225–239, 2008.
   PubMed Web of Science ®Google Scholar
• Stasinopoulos I, Shah T, Penet MF, Krishnamachary B, and Bhujwalla ZM: COX-2 in cancer: Gordian knot or Achilles heel? Front Pharmacol 4, 34, 2013.
   PubMed Web of Science ®Google Scholar
• Lala PK, Parhar RS, and Singh P: Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cell Immunol 99, 108–118, 1986.
   PubMed Web of Science ®Google Scholar
• Deichman GI: Natural host resistance and in vivo selection of malignant tumour cells. Cancer Surv 7, 675–690, 1988.
   PubMedGoogle Scholar
• Ma X, Holt D, Kundu N, Reader J, Goloubeva O, et al.: A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology 2, e22647, 2013.
   PubMed Web of Science ®Google Scholar
• Meron G, Tishler Y, Shaashua L, Rosenne E, Levi B, et al.: PGE2 suppresses NK activity in vivo directly and through adrenal hormones: effects that cannot be reflected by ex vivo assessment of NK cytotoxicity. Brain Behav Immun 28, 128–138, 2013.
   PubMed Web of Science ®Google Scholar
• Christophersen OA: Why is there so much DHA in the brain, retina and testis? Possible implications for human reproduction and the survival of our species. In: Omega-6/3 Fatty Acids: Functions, Sustainability Strategies and Perspectives, De Meester F, Watson RR, Zibadi S, eds. New York: Springer, 2013, 209–244.
   Google Scholar
• Bowry VW, Mohr D, Cleary J, and Stocker R: Prevention of tocopherol-mediated peroxidation in ubiquinol-10-free human low density lipoprotein. J Biol Chem 270, 5756–5763, 1995.
   PubMed Web of Science ®Google Scholar
• Thomas SR, Neuzil J, Mohr D, and Stocker R: Coantioxidants make alpha-tocopherol an efficient antioxidant for low-density lipoprotein. Am J Clin Nutr 62(6 Suppl), 1357S–1364S, 1995.
   PubMed Web of Science ®Google Scholar
• Thomas SR, Neuzil J, and Stocker R: Cosupplementation with coenzyme Q prevents the prooxidant effect of alpha-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation. Arterioscler Thromb Vasc Biol 16, 687–696, 1996.
   PubMed Web of Science ®Google Scholar
• Thomas SR, Neuzil J, and Stocker R: Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis? Mol Aspects Med 18(Suppl), S85–S103, 1997.
   PubMed Web of Science ®Google Scholar
• Lee KH, and Jeong D: Bimodal actions of selenium essential for antioxidant and toxic pro-oxidant activities: the selenium paradox (Review). Mol Med Rep 5, 299–304, 2012.
   PubMed Web of Science ®Google Scholar
• Selenius M, Fernandes AP, Brodin O, Björnstedt M, and Rundlöf AK: Treatment of lung cancer cells with cytotoxic levels of sodium selenite: effects on the thioredoxin system. Biochem Pharmacol 75, 2092–2099, 2008.
   PubMed Web of Science ®Google Scholar
• Selenius M, Rundlöf AK, Olm E, Fernandes AP, and Björnstedt M: Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancer. Antioxid Redox Signal 12, 867–880, 2010.
   PubMed Web of Science ®Google Scholar
• Gopee NV, Johnson VJ, and Sharma RP: Sodium selenite-induced apoptosis in murine B-lymphoma cells is associated with inhibition of protein kinase C-delta, nuclear factor kappaB, and inhibitor of apoptosis protein. Toxicol Sci 78, 204–214, 2004.
   PubMed Web of Science ®Google Scholar
• Gasparian AV, Yao YJ, Lü J, Yemelyanov AY, Lyakh LA, et al.: Selenium compounds inhibit I kappa B kinase (IKK) and nuclear factor-kappa B (NF-kappa B) in prostate cancer cells. Mol Cancer Ther 1, 1079–1087, 2002.
   PubMed Web of Science ®Google Scholar
• Pei Z, Li H, Guo Y, Jin Y, Lin D. Sodium selenite inhibits the expression of VEGF, TGFbeta1 and IL-6 induced by LPS in human PC3 cells via TLR4-NF-κ;B signaling blockage. Int Immunopharmacol 10, 50–56, 2010.
   PubMed Web of Science ®Google Scholar